Authors : Stancil SL; Division of Adolescent Medicine, Children's Mercy Kansas City, Kansas City, Missouri, USA.; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Kansas City, Missouri, USA.

Subjects: Adolescent Psychiatry* ; Anxiety Disorders*/Anxiety Disorders*/Anxiety Disorders*/psychology ; Anxiety Disorders*/Anxiety Disorders*/Anxiety Disorders*/therapy

Source: Clinical and translational science [Clin Transl Sci] 2022 Apr; Vol. 15 (4), pp. 816-823. Date of Electronic Publication: 2022 Jan 10.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Target to treatment: A charge to develop biomarkers of response and tolerability in child and adolescent psychiatry

Authors : Stephani L. Stancil; John Tumberger; Jeffrey R. Strawn

Subjects: Therapeutics. Pharmacology; RM1-950; Public aspects of medicine

Source: Clinical and Translational Science, Vol 15, Iss 4, Pp 816-823 (2022)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Report

From genes to community: exploring translational science in adolescent health research: proceedings from a research symposium.

Authors : Miller E; Division of Adolescent Medicine, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pennsylvania, USA.

Subjects: Adolescent Health Services* ; Genes* ; Residence Characteristics*

Source: Clinical and translational science [Clin Transl Sci] 2012 Dec; Vol. 5 (6), pp. 480-1.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Translational research applications for the study of adolescent sexual decision making.

Authors : Farris C; RAND Corporation, Pittsburgh, PA, USA. ; Akers AY

Subjects: Decision Making* ; Translational Research, Biomedical*; Adolescent Behavior/Adolescent Behavior/Adolescent Behavior/*physiology

Source: Clinical and translational science [Clin Transl Sci] 2013 Feb; Vol. 6 (1), pp. 78-81.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers.

Authors : Badorrek P; Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.; Diefenbach C

Subjects: Bronchiectasis*/Bronchiectasis*/Bronchiectasis*/drug therapy ; Cathepsin C*/Cathepsin C*/Cathepsin C*/antagonists & inhibitors ; Cathepsin C*/Cathepsin C*/Cathepsin C*/metabolism

Source: Clinical and translational science [Clin Transl Sci] 2024 Aug; Vol. 17 (8), pp. e13891.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.

Authors : Shimizu H; Clinical Pharmacology Group, Data Science Department, Ikuyaku, Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.; Tortorici MA

Subjects: Cytochrome P-450 CYP11B2*/Cytochrome P-450 CYP11B2*/Cytochrome P-450 CYP11B2*/antagonists & inhibitors ; Aldosterone*/Aldosterone*/Aldosterone*/blood ; Dose-Response Relationship, Drug*

Source: Clinical and translational science [Clin Transl Sci] 2024 Aug; Vol. 17 (8), pp. e70000.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu-like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll-like receptor 7 agonist ruzotolimod.

Authors : Jiang Q; Roche Innovation Center, Shanghai, China.; Zhang Y

Subjects: Toll-Like Receptor 7*/Toll-Like Receptor 7*/Toll-Like Receptor 7*/agonists ; Healthy Volunteers* ; Hepatitis B, Chronic*/Hepatitis B, Chronic*/Hepatitis B, Chronic*/drug therapy

Source: Clinical and translational science [Clin Transl Sci] 2024 Aug; Vol. 17 (8), pp. e13896.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's disease.

Authors : Koenig A; Sage Therapeutics, Inc, Cambridge, Massachusetts, USA.; Lewis M

Subjects: Huntington Disease*/Huntington Disease*/Huntington Disease*/drug therapy ; Receptors, N-Methyl-D-Aspartate*/Receptors, N-Methyl-D-Aspartate*/Receptors, N-Methyl-D-Aspartate*/antagonists & inhibitors ; Dose-Response Relationship, Drug*

Source: Clinical and translational science [Clin Transl Sci] 2024 Jul; Vol. 17 (7), pp. e13852.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants.

Authors : Miao S; Amgen Inc., Thousand Oaks, California, USA.; Staehr P

Subjects: Electrocardiography* ; Healthy Volunteers* ; Cross-Over Studies*

Source: Clinical and translational science [Clin Transl Sci] 2024 Jul; Vol. 17 (7), pp. e13878.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants.

Authors : Sun ALA; Linear Clinical Research Limited, Nedlands, Western Australia, Australia.; Gillies JD

Subjects: Healthy Volunteers* ; Receptor-Interacting Protein Serine-Threonine Kinases*/Receptor-Interacting Protein Serine-Threonine Kinases*/Receptor-Interacting Protein Serine-Threonine Kinases*/antagonists & inhibitors ; Receptor-Interacting Protein Serine-Threonine Kinases*/Receptor-Interacting Protein Serine-Threonine Kinases*/Receptor-Interacting Protein Serine-Threonine Kinases*/metabolism

Source: Clinical and translational science [Clin Transl Sci] 2024 Jul; Vol. 17 (7), pp. e13857.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Target to treatment: A charge to develop biomarkers of response and tolerability in child and adolescent psychiatry.

Target to treatment: A charge to develop biomarkers of response and tolerability in child and adolescent psychiatry

From genes to community: exploring translational science in adolescent health research: proceedings from a research symposium.

Translational research applications for the study of adolescent sexual decision making.

Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers.

First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.

Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu-like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll-like receptor 7 agonist ruzotolimod.

Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's disease.

A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants.

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants.

اتصل بنا

اتبع